• Thu, September 28, 2017
  • Fri, September 29, 2017
  • Mon, October 2, 2017

Matthew Taylor Maintained (ABT) at Buy with Increased Target to $60 on, Sep 28th, 2017

Matthew Taylor of Barclays, Maintained "Abbott Laboratories" (ABT) at Buy with Increased Target from $57 to $60 on, Sep 28th, 2017.

Matthew has made no other calls on ABT in the last 4 months.



There are 5 other peers that have a rating on ABT. Out of the 5 peers that are also analyzing ABT, 2 agree with Matthew's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Amit Hazan of "Citigroup" Initiated at Hold and Held Target at $53 on, Thursday, August 17th, 2017
  • David Lewis of "Morgan Stanley" Maintained at Hold with Increased Target to $49 on, Monday, July 10th, 2017


These are the ratings of the 3 analyists that currently disagree with Matthew


  • Brittany Henderson of "Deutsche Bank" Maintained at Strong Buy with Increased Target to $56 on, Friday, July 21st, 2017
  • David Toung of "Argus Research" Maintained at Strong Buy with Increased Target to $62 on, Friday, July 21st, 2017
  • Christopher Pasquale of "Guggenheim" Initiated at Strong Buy and Held Target at $58 on, Thursday, June 29th, 2017